Figure 1. MAPK and AKT are activated in HRMECs by VEGFA165a and VEGFA165b. A: Immunoblots of total MAPK and activated MAPK (phospho-MAPK) 10 min after treatment with VEGFA165a (Va), VEGFA165b (Vb), or media control (C). Two representative experiments are shown. B: Immunoblots of total AKT and activated AKT (phospho-AKT) 10 min after treatment with VEGFA165a (Va), VEGFA165b (Vb), or media control (C). Two representative experiments are shown. C: Fold activation of MAPK and AKT from three immunoblotting experiments. P values are shown, t test relative to media controls (onefold).
Figure 1 of
Dailey, Mol Vis 2021; 27:191-xxx.